Treatment of poisoning caused by β-adrenergic and calcium-channel blockers

American Journal of Health-System Pharmacy

Volumn 63, Issue 19, 2006, Pages 1828-1835

  Shepherd, Greene ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Amrinone; Antidotes; Calcium; Calcium antagonists; Combined therapy; Dextrose; Dosage; Epinephrine; Glucagon; Insulin; Phosphodiesterase inhibitors; Poisoning; Potassium; Sympatholytic agents; Sympathomimetic agents; Toxicity

Indexed keywords

ACEBUTOLOL; ACTIVATED CARBON; ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARTEOLOL; CARVEDILOL; ESMOLOL; GLUCAGON; GLUCONATE CALCIUM; GLUCOSE; INSULIN; LABETALOL; METOPROLOL; NADOLOL; OXPRENOLOL; PENBUTOLOL; PHOSPHODIESTERASE INHIBITOR; PINDOLOL; POTASSIUM; PROPRANOLOL; SOTALOL; UNINDEXED DRUG;

BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CARDIOTOXICITY; DRUG INTOXICATION; DRUG MEGADOSE; DRUG SOLUBILITY; FLUID THERAPY; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INTESTINE LAVAGE; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPID SOLUBILITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STOMACH LAVAGE;

EID: 33749162813     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060041     Document Type: Review

References (28)

1. Watson WA, Litovitz TL, Rodgers GC Jr. et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2005; 23:589-666.
2. Salhanick S, Shannon M. Management of calcium channel antagonist overdose. Drug Saf. 2003; 26:65-79.
3. Kerns W II, Kline J, Ford MD. Beta-blocker and calcium channel blocker toxicity. Emerg Med Clin North Am. 1994; 12:365-90.
4. Buscher R, Herrmann V, Insel PA. Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Trends Pharmacol Sci. 1999; 20:94-9.
5. Leikin JB, Paloucek FP. Leikin & Paloucek's poisoning & toxicology handbook. 3rd ed. Hudson, OH: Lexi-Comp; 2002.
6. Sunaga K, Ogihara M. Effects of calcium channel blockers and hydralazine on plasma glucose levels in streptozotocin-induced diabetic rats in vivo. Jpn J Pharmacol. 1990; 52:449-55.
7. Wax PM, Erdman AR, Chyka PA et al. Beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2005; 43:131-46.
8. Olson KR, Erdman AR, Woolf AD et al. Calcium channel blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2005; 43:797-822.
9. Critchley JA, Ungar A. The management of acute poisoning due to beta-adrenoceptor antagonists. Med Toxicol Adverse Drug Exp. 1989; 4:32-45.
10. Reith DM, Dawson AH, Epid D et al. Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol. 1996; 34:273-8.
11. Love JN, Howell JM, Litovitz TL et al. Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol. 2000; 38:275-81.
12. Kline JA, Raymond RM, Leonova ED et al. Insulin improves heart function and metabolism during non-ischemic cardiogenic shock in awake canines. Cardiovasc Res. 1997; 34:289-98.
13. Shepherd G, Klein-Schwartz W. High dose insulin therapy for calcium channel blocker overdose. Ann Pharmacother. 2005; 39:923-30.
14. Kline JA, Raymond RM, Schroeder JD et al. The diabetogenic effects of acute verapamil poisoning. Toxicol Appl Pharmacol. 1997; 145:357-62.
15. Krenzelok E, Vale A. Position statements: gut decontamination. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1997; 35:695-786.
16. American College of Emergency Physicians. Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med. 1995; 25:570-85.
17. Dart RC, Stark Y, Fulton B et al. Insufficient stocking of poisoning antidotes in hospital pharmacies. JAMA. 1996; 276:1508-10.
18. Dart RC, Goldfrank LR, Chyka PA et al. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med. 2000; 36:126-32.
19. Love JN, Leasure JA, Mundt DJ et al. A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propranolol toxicity in a canine model. J Toxicol Clin Toxicol. 1992; 30:399-412.
20. Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol. 2003; 41:595-602.
21. Holger JS, Engebretsen KM, Obetz CL et al. A comparison of vasopressin and glucagon in beta-blocker induced toxicity. Clin Toxicol. 2006; 44:45-51.
22. Ward DE, Jones B. Glucagon and beta-blocker toxicity. Br Med J. 1976; 2:151.
23. Glucagon for injection package insert. Indianapolis, IN: Eli Lilly Co; 2006 Apr.
24. Kerns W II, Schroeder D, Williams C et al. Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med. 1997; 29:748-57.
25. Sztajnkrycer MD, Bond GR, Johnson SB et al. Use of vasopressin in a canine model of severe verapamil poisoning: a preliminary descriptive study. Acad Emerg Med. 2004; 11:1253-61.
26. Kline JA, Tomaszewski CA, Schroeder JD et al. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther. 1993; 267:744-50.
27. Kline JA, Leonova E, Williams TC et al. Myocardial metabolism during graded intraportal verapamil infusion in awake dogs. J Cardiovasc Pharmacol. 1996; 27:719-26.
28. Kline JA, Leonova E, Raymond RM. Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine. Crit Care Med. 1995; 23:1251-63.